On the public citation graph

Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study

0 signed · 59 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamadermatol.2017.4584openalex-snapshot
Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma
inferredcites →https://doi.org/10.1001/jamaoncol.2018.0013openalex-snapshot
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
inferredcites →https://doi.org/10.1001/jamaoncol.2020.3370openalex-snapshot
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
inferredcites →https://doi.org/10.1007/s10555-016-9652-yopenalex-snapshot
Next generation predictive biomarkers for immune checkpoint inhibition
inferredcites →https://doi.org/10.1016/j.annonc.2023.10.038openalex-snapshot
LBA44 Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
inferredcites →https://doi.org/10.1016/j.ctrv.2018.02.005openalex-snapshot
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
inferredcites →https://doi.org/10.1016/j.immuni.2018.03.014openalex-snapshot
Regulation and Function of the PD-L1 Checkpoint
inferredcites →https://doi.org/10.1016/j.jtho.2018.04.025openalex-snapshot
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
inferredcites →https://doi.org/10.1016/j.ygyno.2021.08.018openalex-snapshot
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
inferredcites →https://doi.org/10.1016/s0140-6736(18)32409-7openalex-snapshot
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30406-5openalex-snapshot
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
inferredcites →https://doi.org/10.1016/s1470-2045(19)30388-2openalex-snapshot
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
inferredcites →https://doi.org/10.1016/s2214-109x(22)00501-0openalex-snapshot
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative
inferredcites →https://doi.org/10.1056/nejmoa1309748openalex-snapshot
Improved Survival with Bevacizumab in Advanced Cervical Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1716948openalex-snapshot
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
inferredcites →https://doi.org/10.1056/nejmoa1816714openalex-snapshot
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1915745openalex-snapshot
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa2112187openalex-snapshot
Survival with Cemiplimab in Recurrent Cervical Cancer
inferredcites →https://doi.org/10.1056/nejmoa2112435openalex-snapshot
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
inferredcites →https://doi.org/10.1093/annonc/mdz110openalex-snapshot
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
inferredcites →https://doi.org/10.1097/cm9.0000000000002108openalex-snapshot
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
inferredcites →https://doi.org/10.1111/1759-7714.13241openalex-snapshot
Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
inferredcites →https://doi.org/10.1126/science.aaf2834openalex-snapshot
The “cancer immunogram”
inferredcites →https://doi.org/10.1136/jitc-2020-002223openalex-snapshot
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-1116openalex-snapshot
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-2980openalex-snapshot
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
inferredcites →https://doi.org/10.1200/jco.18.01265openalex-snapshot
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
inferredcites →https://doi.org/10.1200/jco.19.00739openalex-snapshot
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
inferredcites →https://doi.org/10.1200/jco.19.02446openalex-snapshot
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
inferredcites →https://doi.org/10.1200/jco.20.01920openalex-snapshot
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
inferredcites →https://doi.org/10.1200/jco.2017.74.3062openalex-snapshot
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
inferredcites →https://doi.org/10.1200/jco.2017.74.5471openalex-snapshot
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.3604openalex-snapshot
Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).
inferredcites →https://doi.org/10.1200/jco.2022.40.16_suppl.5536openalex-snapshot
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
inferredcites →https://doi.org/10.1200/jco.21.02091openalex-snapshot
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
inferredcites →https://doi.org/10.1200/po.19.00171openalex-snapshot
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.21037/atm-21-2315openalex-snapshot
Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer
inferredcites →https://doi.org/10.3322/caac.21763openalex-snapshot
Cancer statistics, 2023
inferredcites →https://doi.org/10.3390/cancers12010230openalex-snapshot
Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
inferredcites →https://doi.org/10.6004/jnccn.2022.0025openalex-snapshot
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5044981openalex-extracted
Efficacy and Safety of Immune Checkpoint Inhibitors Combined with TKIs for Recurrent or Metastatic Cervical Cancer with PIK3CA Mutation: A Secondary Analysis Based on Two Prospective Studies
inferred← citeshttps://doi.org/10.1002/cai2.70070openalex-snapshot
Low‐Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.1002/ijgo.70280openalex-snapshot
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives
inferred← citeshttps://doi.org/10.1007/s00405-025-09482-xopenalex-snapshot
Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis
inferred← citeshttps://doi.org/10.1016/j.canlet.2025.218135openalex-snapshot
Current landscape of cross-line immune checkpoint blockade for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.ijgc.2025.102718openalex-snapshot
Distribution and maturity of tertiary lymphoid structures predict recurrence-free survival in cervical cancer
inferred← citeshttps://doi.org/10.1097/coc.0000000000001352openalex-snapshot
PD-1 Inhibition With Camrelizumab in Cervical Cancer
inferred← citeshttps://doi.org/10.1136/jitc-2025-012539openalex-snapshot
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis
inferred← citeshttps://doi.org/10.1136/jitc-2026-015554openalex-snapshot
Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer
inferred← citeshttps://doi.org/10.1186/s12916-025-04198-5openalex-snapshot
Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0350571openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1679950openalex-snapshot
Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1686568openalex-snapshot
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1747768openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1780752openalex-snapshot
PIK3CA mutation–induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy
inferred← citeshttps://doi.org/10.3389/fonc.2024.1454372openalex-snapshot
Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2026.1742990openalex-snapshot
Cervical cancer with BRCA1 gene mutations: case reports and literature review
inferred← citeshttps://doi.org/10.3892/ol.2025.15095openalex-snapshot
Pancreatic metastasis from cervical cancer: A case report and literature review
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.